
OmegaQuant launches prenatal DHA test to help pregnant women determine risk for preterm birth
OmegaQuant Analytics, the producer of The Omega-3 Index, has launched a new Prenatal DHA Test developed for expecting mothers to monitor their omega-3 DHA level.
OmegaQuant Analytics (Siox Falls, SD), the producer of The Omega-3 Index, has launched a new Prenatal DHA Test developed for expecting mothers to monitor their omega-3 DHA level. This is an important measure for pregnant women because there is evidence that deficiency in omega-3 long chain polyunsaturated fatty acids can increase the risk of preterm birth.
A
Using this data, and converting the EPA and DHA plasma levels to red blood cell DHA levels, OmegaQuant determined that pregnant women should strive to have DHA levels of at least 5% (meaning that 5% of her red blood cell fatty acids are DHA). “In a
References:
1. Middleton P. et al. “Omega-3 fatty acid addition during pregnancy.” Cochrane Database of Systematic Reviews, vol 11 (November 2018)
2. Olsen S.F. et al. “Plasma concentrations of long chain omega-3 fatty acids in early and mid-pregnancy and risk of early preterm birth.” EBioMedicine, vol 35 (September 2018): 325-333
3. Jackson K.H et al. “A prenatal DHA test to help identify women at increased risk for early preterm birth: a proposal.” Nutrients, vol 10, no. 12 (December 2018)
Newsletter
From ingredient science to consumer trends, get the intel you need to stay competitive in the nutrition space—subscribe now to Nutritional Outlook.





